KRAS mutant lung cancers have been divided into three groups by integrating genomic, transcriptomic, and proteomic analyses: TP53-inactivated, CDKN2A/B-inactivated, and LKB1-inactivated [15]. This evidence concerns the gene CDKN2A and lung carcinoma.